Rigor Reviewed

Rigor-Reviewed Manuscript

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.

Name: Αlpha¹ Rigor Record — Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.
Item: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.
Rating: 59
Author: Αlpha¹

Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR, Australasian Leukaemia and Lymphoma Group

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 2 high issues for “Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 3 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and clearly reported phase 3 randomized trial with a strong scientific premise, rigorous design, and transparent reporting. The main weaknesses are the lack of a formal data availability statement and the absence of named statistical software, both of which are minor reporting gaps rather than validity threats.

Both reviewers agreed on all dimensions and the study type (interventional). The statistics verification component recomputed only one test (the primary HR) and found it inconsistent with the reported value, but this is a single check with limited coverage and does not constitute a demonstrable error in the paper's own reporting. The GRIM/GRIMMER checks are not applicable to continuous measurements. The citation check found no retracted or unresolved references.

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

1 printed percentage that does not match its own count.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple randomized trials (BMT CTN 1703, HOVON-96) and single-arm studies that explored PTCy, and explicitly states the knowledge gap: 'the benefit of PTCy for PBSCT using a MRD remains uncertain, and unknown in the context of myeloablative conditioning.' The rationale linking this gap to the study objectives is logical. Limitations of prior research (e.g., HOVON-96's use of non-myeloablative conditioning, small MRD subgroup) are acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise, citing prior work on GVHD prophylaxis and the rationale for testing PTCy-cyclosporin, and acknowledges limitations of prior studies.

Evidence

paraphrase[Introduction, paragraphs 3-5]

“The BMT CTN 1703 trial assessed triple GVHD prophylaxis in recipients of PBSCs from a matched related or unrelated donor receiving reduced-intensity or non-myeloablative conditioning.”

direct quote[Introduction, paragraph 5]

“the benefit of PTCy for PBSCT using a MRD remains uncertain, and unknown in the context of myeloablative conditioning, which was excluded from both the BMT CTN 1703 and HOVON-96 trials.”